Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121179392 | 12117939 | 2 | F | 20160921 | 20160226 | 20160927 | EXP | NO-009507513-1602NOR010741 | MERCK | 0.00 | Y | 0.00000 | 20160927 | OT | SE | NO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121179392 | 12117939 | 1 | PS | PEGINTRON | PEGINTERFERON ALFA-2B | 1 | Subcutaneous | 15 MICROGRAM, QW, FROM END OF MONTH 3 (M3) TO M6 | U | 103949 | 15 | UG | POWDER FOR INJECTION | /wk | |||||
| 121179392 | 12117939 | 2 | SS | PEGINTRON | PEGINTERFERON ALFA-2B | 1 | Subcutaneous | 25 MICROGRAM, QW, UNTIL M15 | U | 103949 | 25 | UG | POWDER FOR INJECTION | /wk | |||||
| 121179392 | 12117939 | 3 | SS | SPRYCEL | DASATINIB | 1 | 100 MG, QD, AS SINGLE DRUG FOR THREE MONTHS | U | 0 | 100 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 121179392 | 12117939 | 1 | Chronic myeloid leukaemia |
| 121179392 | 12117939 | 3 | Chronic myeloid leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 121179392 | 12117939 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 121179392 | 12117939 | Headache | |
| 121179392 | 12117939 | Malaise | |
| 121179392 | 12117939 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |